|
*** PAXIL*** The Fox Law Firm is Reviewing Potential PAXIL Claims
PPH Depression Lung Disorders
Have you experienced severe health issues following the use of Paxil? Have your loved ones suffered adversely after taking the drug? If so, you should contact us immediately to protect your legal rights. If you or your loved ones have experienced any of these side effects you may have a claim for legal compensation. Contact The Fox Law Firm for superior legal representation. Classified specifically as a Selective Serotonin Reuptake Inhibitor (SSRI) antidepressant, Paxil – which is a trade-name of Paroxetine - was released onto the market in 1992 by the pharmaceutical company GlaxoSmithKline. Paxil can be utilized in the treatment of such conditions as obsessive-compulsive disorder, panic-attacks, heightened states of anxiety, and depression. Paxil was the first antidepressant that received approval within the U.S. for the treatment of panic-attacks. Paxil has the effect of balancing the patient’s Serotonin levels - a naturally-occurring substance in the brain – and assists with the improvement and positive regulation of the patient’s mood. Some of the less serious side-effects that the use of Paxil can cause include: both weight loss and weight gain; headaches; nausea; excessive perspiration; sleeping problems; constipation; and noticeable changes in bowel movements. Far more serious side-effects have been reported, too, however. For example, in July 2006, the Food and Drug Administration (FDA) reported on the conclusions of two separate reports that revealed serious reactions had occurred in patients that had been prescribed Paxil. The FDA began by summarizing the findings of a report that appeared in the February 1, 2006 issue of the Journal of the American Medical Association (JAMA). The FDA said that the authors behind the study had followed the experiences of a number of pregnant women who had battled severe depression. During the period of their pregnancies, the FDA added, a number of the women no longer suffering from depression stopped taking their antidepressant medicines. Others, however, decided to remain on their antidepressant medicines while they were still pregnant. The study, said the FDA, demonstrated that the patients who ceased taking their medicine during pregnancy were approximately five times more likely to relapse into depressive states than were those who chose to continue with their antidepressant medicines while they were pregnant. The second report addressed by the FDA – which appeared in the pages of the February 9, 2006 edition of the New England Journal of Medicine – dealt with reports of newborn babies affected by Persistent Pulmonary Hypertension of the Newborn (PPHN): a serious and potentially life-threatening lung-related condition that occurs very soon after birth. Babies affected by PPHN have elevated pressure in the blood vessels of their lungs, and are unable to get adequate amounts of oxygen into their bloodstream. Around 1 to 2 babies per 1000 babies who are born in the United States every year go on to develop PPHN shortly after birth. Intensive medical care is very often required to treat the condition. In the New England Journal of Medicine report, PPHN was described as being around six times more common in babies whose mothers took an SSRI antidepressant after the 20th week of the pregnancy than in those babies whose mothers were not taking prescribed SSRI’s. Additional Information:
|
